These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 9022606)

  • 1. Progesterone levels on the day of human chorionic gonadotropin do not predict pregnancy outcome from the transfer of fresh or cryopreserved embryos from the same cohort.
    Moffitt DV; Queenan JT; Shaw R; Muasher SJ
    Fertil Steril; 1997 Feb; 67(2):296-301. PubMed ID: 9022606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triggering of final oocyte maturation with gonadotropin-releasing hormone agonist or human chorionic gonadotropin. Live birth after frozen-thawed embryo replacement cycles.
    Griesinger G; Kolibianakis EM; Papanikolaou EG; Diedrich K; Van Steirteghem A; Devroey P; Ejdrup Bredkjaer H; Humaidan P
    Fertil Steril; 2007 Sep; 88(3):616-21. PubMed ID: 17451691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
    Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
    Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An increased serum progesterone-to-estradiol ratio on the day of human chorionic gonadotropin administration does not have a negative impact on clinical pregnancy rate in women with normal ovarian reserve treated with a long gonadotropin releasing hormone agonist protocol.
    Lai TH; Lee FK; Lin TK; Horng SG; Chen SC; Chen YH; Wang PC
    Fertil Steril; 2009 Aug; 92(2):508-14. PubMed ID: 18701101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The benefit of human chorionic gonadotropin supplementation throughout the secretory phase of frozen-thawed embryo transfer cycles.
    Ben-Meir A; Aboo-Dia M; Revel A; Eizenman E; Laufer N; Simon A
    Fertil Steril; 2010 Feb; 93(2):351-4. PubMed ID: 19342020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
    Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
    Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum progesterone level effects on the outcome of in vitro fertilization in patients with different ovarian response: an analysis of more than 10,000 cycles.
    Xu B; Li Z; Zhang H; Jin L; Li Y; Ai J; Zhu G
    Fertil Steril; 2012 Jun; 97(6):1321-7.e1-4. PubMed ID: 22494924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A prospective, randomized controlled study comparing the effects of gonadotropin-releasing hormone agonist long and short protocols for in vitro fertilization].
    Ye H; Huang G; Pei L
    Zhonghua Fu Chan Ke Za Zhi; 2001 Apr; 36(4):222-5. PubMed ID: 11783366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization.
    Schmidt DW; Maier DB; Nulsen JC; Benadiva CA
    Fertil Steril; 2004 Oct; 82(4):841-6. PubMed ID: 15482757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased progesterone/estradiol ratio on the day of HCG administration adversely affects success of in vitro fertilization-embryo transfer in patients stimulated with gonadotropin-releasing hormone agonist and recombinant follicle-stimulating hormone.
    Ou YC; Lan KC; Chang SY; Kung FT; Huang FJ
    Taiwan J Obstet Gynecol; 2008 Jun; 47(2):168-74. PubMed ID: 18603501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical effects of ovulation induction with recombinant follicle-stimulating hormone supplemented with recombinant luteinizing hormone or low-dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders.
    Berkkanoglu M; Isikoglu M; Aydin D; Ozgur K
    Fertil Steril; 2007 Sep; 88(3):665-9. PubMed ID: 17292895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cryopreserved-thawed embryo transfer in natural or down-regulated hormonally controlled cycles: a retrospective study.
    Gelbaya TA; Nardo LG; Hunter HR; Fitzgerald CT; Horne G; Pease EE; Brison DR; Lieberman BA
    Fertil Steril; 2006 Mar; 85(3):603-9. PubMed ID: 16500326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum progesterone at human chorionic gonadotropin injection significantly correlate with female age.
    Doldi N; Persico P; De Santis L; Rabellotti E; Papaleo E; Ferrari A
    Minerva Ginecol; 2005 Aug; 57(4):477-82. PubMed ID: 16170294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A GnRH agonist and exogenous hormone stimulation protocol has a higher live-birth rate than a natural endogenous hormone protocol for frozen-thawed blastocyst-stage embryo transfer cycles: an analysis of 1391 cycles.
    Hill MJ; Miller KA; Frattarelli JL
    Fertil Steril; 2010 Feb; 93(2):416-22. PubMed ID: 19171338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
    Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T
    Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Luteinizing hormone concentrations after gonadotropin-releasing hormone antagonist administration do not influence pregnancy rates in in vitro fertilization-embryo transfer.
    Merviel P; Antoine JM; Mathieu E; Millot F; Mandelbaum J; Uzan S
    Fertil Steril; 2004 Jul; 82(1):119-25. PubMed ID: 15236999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Premature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles.
    Kiliçdag EB; Haydardedeoglu B; Cok T; Hacivelioglu SO; Bagis T
    Arch Gynecol Obstet; 2010 Apr; 281(4):747-52. PubMed ID: 19862542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does high serum progesterone level on the day of human chorionic gonadotropin administration affect pregnancy rate after intracytoplasmic sperm injection and embryo transfer?
    Azem F; Tal G; Lessing JB; Malcov M; Ben-Yosef D; Almog B; Amit A
    Gynecol Endocrinol; 2008 Jul; 24(7):368-72. PubMed ID: 18645708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer.
    Doldi N; Persico P; Di Sebastiano F; Marsiglio E; Ferrari A
    Gynecol Endocrinol; 2006 May; 22(5):235-8. PubMed ID: 16785142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cryopreservation of supernumerary high quality embryos predicts favorable outcomes for patients undergoing repeated cycles of in vitro fertilization.
    Wang JG; Douglas NC; Dicken C; Nakhuda GS; Guarnaccia MM; Sauer MV
    Fertil Steril; 2008 Feb; 89(2):368-74. PubMed ID: 17509594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.